Scientific Advisory Board

The Scientific Advisory Board (SAB) of CurePSP, advises the Board of Directors on scientific and medical matters, assists with the educational and research activities of the organization, and reviews research grant applications/proposals on a semi-annual basis. Voting members of the Scientific Advisory Board are prominent scientists and clinicians with expertise pertinent to PSP and CBD genetics, pathology, pathophysiology, clinical manifestations, and management.

Lawrence I. Golbe, MD (Chair)
Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey

Edward A. Burton, MD, DPhil, FRCP
University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania

Ted M. Dawson, MD
Johns Hopkins University School of Medicine, Baltimore, Maryland

Dennis W. Dickson, MD
Mayo Clinic, Jacksonville, Florida

Michael Gold, MS, MD
UCB, Inc., Raleigh, North Carolina

Jason Gestwicki, PhD
University of California, San Francisco, San Francisco, California

Günter U. Höglinger, MD
German Center for Neurodegenerative Diseases & Technical University Munich, Munich, Germany

Virginia M.-Y. Lee, PhD
Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania

Irene Litvan, MD
University of California, San Diego, San Diego, California

Huw R. Morris, PhD, FRCP
National Hospital for Neurology and Neurosurgery and UCL Institute of Neurology, London, England

Christiane Richter-Landsberg, PhD
Institute of Biology, University of Oldenburg, Oldenburg, Germany

Gerard D. Schellenberg, PhD
University of Pennsylvania, School of Medicine, Philadelphia, Pennsylvania

David Kemp (Ex Officio)
President, CurePSP

Medical Advisory Board

Lawrence I. Golbe, MD
Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey

Irene Litvan, MD
University of California, San Diego, San Diego, California

Alexander Patelyat, MD
Johns Hopkins University, Baltimore, Maryland

Brent Bluett, DO
Cleveland Clinic, Las Vegas, Nevada